8-K ·Filed May 18, 2026

INVA

Innoviva, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed4mo ago SEC0001193125-26-228958
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

Routine board refresh with no financial or strategic implications. No trading catalyst. Monitor for any future disclosures on Innoviva's investment trajectory in Syndeio BioSciences, but this filing alone does not warrant action.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
INVA ▼ -4.51% at T+60d
NEUTRAL call ✗ call lost -4.51% · α vs SPY -10.80% · entry $21.73 → $20.75
Entry anchored
May 18, 2026
via day open
T+1d
+2.35%
call +2.35% · α +1.31%
$22.24
settled 5mo ago
T+5d
+1.84%
call +1.84% · α -0.46%
$22.13
settled 4mo ago
T+20d
+4.19%
call +4.19% · α +3.20%
$22.64
settled 4mo ago
T+60d
-4.51%
call -4.51% · α -10.80%
$20.75
settled 7w ago

Price Chart

Loading chart...

Executive Summary

Innoviva reported the resignations of board members Derek Small and Mark DiPaolo to focus on their roles at Syndeio BioSciences, a company Innoviva has invested in and continues to support. The board elected Josephine Linden, a former Goldman Sachs partner and founder of Linden Global Strategies, as an independent director to fill the vacancies. This is a routine board transition with no disagreements disclosed, representing a neutral event for the company's operations.

Key Facts

  • Derek Small and Mark DiPaolo resigned from the board on May 12, 2026, to focus on Syndeio BioSciences.
  • Resignations were not due to any disagreement with Innoviva's operations, policies, or practices.
  • Josephine Linden elected to the board on May 18, 2026, as an independent director, expected to serve on the Audit Committee.
  • Linden is the founder of Linden Global Strategies LLC and a retired Goldman Sachs Partner and Managing Director.
  • Linden receives initial RSU award of $125,000, prorated annual RSU award of $206,250, and options for 9,166 shares under the 2026 Equity Incentive Plan.
  • No material transactions between Innoviva and Linden exceeding $120,000.

Financial Impact

New director compensation: $125,000 initial RSU, $206,250 prorated annual RSU, and options for 9,166 shares. Immaterial relative to $1.6B market cap.

share countdilution

Risk Factors

  • Loss of board members with direct ties to Syndeio may reduce board-level insight into that investment.
  • New director is independent and highly qualified, but the transition introduces a short period of adjustment.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
82% bullish (11 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-228958
Document: 0001193125-26-228958-index-headers.html0001193125-26-228958
Document: 0001193125-26-228958-index.html0001193125-26-228958
Document: 0001193125-26-228958.txt0001193125-26-228958
3 reports for INVA
Performance horizon
Filters
Rows
Reports for INVA — sortable, filterable
TypeNow
May 18, 2026
19w ago
8-K
NEUTRAL ★ 3/10
$21.73 $20.75▼ −4.51%▼ −10.80%$20.50 (−5.66%)
May 6, 2026
21w ago
8-K
MIXED ★ 5/10
$22.80 $20.77▼ −8.90%▼ −12.74%$20.50 (−10.09%)
Mar 27, 2026
27w ago
10-K/A
NEUTRAL ★ 3/10
$22.91 $23.35▲ +1.92%▼ −14.57%$20.50 (−10.52%)
Showing 3 of 3

US Market Status

Market Closed — Opens Mon (64h 38m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access